Table 3 Cases of COVID-19 in French children with Prader-Willi syndrome between March 2020 and January 2021
Clinical characteristics (n = 13) | |
Age (years) | 9.6 ± 4.4 [1.9–18] |
Gender (%) | Female 5 (38); Male 8 (62) |
Genetic subtype (%) | Deletion: 8 (62); UPD: 5 (38) |
Body Mass Index (kg/m2) | 21.8 ± 10.9 |
BMI Z-score | 1.3 (-2.1–7.7) |
Obesity (BMI Z-score ≥ 3) | 3 (23) |
Type 1 or 2 diabetes | 0 |
Treated apnea syndrome with nocturnal CPAP (%) | 2 (15) |
Hypertension | 0 |
Congenital heart defect (%) | 1 (8) |
Respiratory and/or cardiac failure (%) | 0 |
Living situation at the time of COVID-19 (%) | |
Living home with family | 13 (100) |
Residential group home | 0 |
Treatments at the time of COVID-19 (%) | |
Growth hormone | 13 (100) |
Thyroxine | 8 (62) |
Hydrocortisone | 1 (8) |
Sex Hormone therapy | 1 (8) |
Vitamin D | 11 (85) |
Topiramate | 1 (8) |
Antipsychotics | 1 (8) |
COVID-19 diagnosis (%) | |
Positive SARS-CoV-2 RT-PCR test | 6 (46) |
Positive IgG against SARS-CoV-2 after infection | 1 (8) |
Suspected diagnosis* | 6 (46) |
Plaints or clinical signs (%) | 10 (77) |
Asthenia | 5 (38) |
Fever | 4 (31) |
Cough | 3 (23) |
Muscle pain | 1 (8) |
Chest tightness | 1 (8) |
Headache | 4 (31) |
Diarrhea | 2 (15) |
Not eating | 2 (15) |
Anosmia | 1 (8) |
No clinical sign or plaints | 3 (23) |
Evolution of symptomatic patients (%) | |
Hospitalization | 0 |
Death | 0 |
Complete recovery | 9 (90) |
Time to complete recovery (days) | 7.7 ± 5.9 [1–20] |
Partial recovery | 1 (persistent asthenia) |